Content about Acquisition

October 18, 2011

Par Pharmaceutical Cos. has acquired the rights to three generic drugs from another company.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has acquired the rights to three generic drugs from another company.

Par said it has acquired from Teva Pharmaceutical Industries the abbreviated new drug applications for fentanyl citrate lozenges and cyclobenzaprine ER capsules (generic versions of Actiq and Amrix, respectively), as well as the U.S. rights to market modafinil tablets, the generic version of Provigil. The acquired rights were in connection to Teva's acquisition of drug maker Cephalon, which was completed Friday.

October 11, 2011

The retirement of Katz Group Canada CEO Andy Giancamilli come February will mark the rise of pharmacy veteran Frank Scorpiniti, who will take the helm of the Canadian retailer.


MISSISSAUGA, Ontario — The retirement of Katz Group Canada CEO Andy Giancamilli come February will mark the rise of pharmacy veteran Frank Scorpiniti, who will take the helm of the Canadian retailer.


Scorpiniti joined Katz Group Canada in April 2011 as COO. Long regarded as one of the bright young executives in retail pharmacy, Scorpiniti now will get a chance to lead a progressive Canadian pharmacy chain, with a hot new Rexall Healthy Living concept, a national presence under Rexall and a slew of innovative programs like the employer-based Rexall Network program.


October 7, 2011

Unilever’s Gina Boswell, who was recently appointed EVP personal care for North America, has been selected as a 2011 Achiever of the Year, one of the highest awards bestowed in the beauty industry, by nonprofit Cosmetic Executive Women.

ENGLEWOOD CLIFFS, N.J. — Unilever’s Gina Boswell, who was recently appointed EVP personal care for North America, has been selected as a 2011 Achiever of the Year, one of the highest awards bestowed in the beauty industry, by nonprofit Cosmetic Executive Women.

This year’s honorees will be feted Oct. 14 at the Waldorf Astoria in New York.

October 5, 2011

AccuDial Pharmaceutical on Tuesday acquired Stephen Key Design in a move that will expand AccuDial’s patent portfolio to more than 50 patents for weight-based dosing and other extended content rotating labels, which add 75% more labeling space to a container.

PALM BEACH GARDENS, Fla. — AccuDial Pharmaceutical on Tuesday acquired Stephen Key Design in a move that will expand AccuDial’s patent portfolio to more than 50 patents for weight-based dosing and other extended content rotating labels, which add 75% more labeling space to a container.

September 27, 2011

AmerisourceBergen on Tuesday purchased TheraCom, a subsidiary of CVS Caremark that provides a wide range of support to pharmaceutical and biotechnology drug manufacturers, including consulting and reimbursement services, for $250 million.

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday purchased TheraCom, a subsidiary of CVS Caremark that provides a wide range of support to pharmaceutical and biotechnology drug manufacturers, including consulting and reimbursement services, for $250 million.

TheraCom is a provider of commercialization support services to the biotech and pharmaceutical industry, specifically, providing reimbursement and patient access support services, and will join Lash Group as part of AmerisourceBergen Consulting Services.

September 21, 2011

The offering period for Pfizer's acquisition of Icagen has expired, allowing the former to purchase more than 5 million shares in the company, Pfizer said.

NEW YORK — The offering period for Pfizer's acquisition of Icagen has expired, allowing the former to purchase more than 5 million shares in the company, Pfizer said.

Pfizer said that as of Monday, 5.4 million shares of Icagen had been put up for sale. Along with the 1.1 million shares Pfizer already owns, this would give it control of 70.2% of Icagen, which develops drugs for pain and other conditions. Pfizer plans to acquire the remaining shares as well.

September 15, 2011

Insight Pharmaceuticals recently acquired the Monistat North American brand portfolio from McNeil and is establishing itself as the premier distributor of women's health over-the-counter products.

LANGHORNE, Pa. — Insight Pharmaceuticals recently acquired the Monistat North American brand portfolio from McNeil and is establishing itself as the premier distributor of women's health over-the-counter products.

September 15, 2011

Wal-Mart Stores marked a major investment in social media and marketing with the announcement Wednesday that its technology unit @WalmartLabs has acquired mobile and social advertising firm OneRiot.

BRISBANE, Calif. — Wal-Mart Stores marked a major investment in social media and marketing with the announcement Wednesday that its technology unit @WalmartLabs has acquired mobile and social advertising firm OneRiot.

September 12, 2011

McKesson on Monday announced the creation of a new division: McKesson Specialty Health.

THE WOODLANDS, Texas — McKesson on Monday announced the creation of a new division: McKesson Specialty Health.

Less than a year ago, McKesson Corporation acquired US Oncology with a vision of enhancing its customer offerings. Through integrated technology offerings, including iKnowMed, a top-ranked Web-based oncology electronic health record, and the Lynx Mobile drug inventory management system, McKesson Specialty Health hopes to improve the financial health of its customers, while empowering them to advance the science, quality and efficiency of patient care.

September 12, 2011

The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO.

EXECUTIVE NEWS — The Generic Pharmaceutical Association has named Ralph Neas as its new president and CEO. Neas, currently president and CEO of the National Coalition on Health Care, replaces Kathleen Jaeger, who stepped down as president and CEO of GPhA in May 2010 after eight years with the organization. The GPhA said it planned to spend September introducing Neas to stakeholders in a broad outreach effort.


September 8, 2011

Merck KGaA announced that Robert Yates was named president of Merck Millipore, the drug maker's life science division.

DARMSTADT, Germany — Merck KGaA announced that Robert Yates was named president of Merck Millipore, the drug maker's life science division.

Yates will report to Bernd Reckmann, who leads the company's chemicals business sector, which includes the Merck Millipore and performance materials division. Millipore was acquired by Merck in July 2010.

Prior to his new role, Yates worked at Roche for 22 years, most recently in Roche's diagnostics division, where he led the life sciences business in Penzberg, Germany.

September 6, 2011

Pfizer has completed its initial cash tender offer for all the shares of drug maker Icagen that it doesn't already own, Pfizer said Tuesday.

NEW YORK — Pfizer has completed its initial cash tender offer for all the shares of drug maker Icagen that it doesn't already own, Pfizer said Tuesday.

Pfizer, which already owns an 11% stake in Icagen, announced Thursday that it would acquire a majority stake in the company. As of Friday, when the initial tender offer period expired, about 4.6 million shares of Icagen had been put up for sale; combined with Pfizer's existing stake, this represents about 64% of the North Carolina-based maker of drugs for pain, epilepsy and inflammation.

September 1, 2011

Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

NEW YORK — Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

August 24, 2011

The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


In May, Teva beat out Valeant’s $5.7 billion offer to buy Frazier, Pa.-based Cephalon with a $6.8 billion offer of its own, acquiring Cephalon’s hefty pipeline in the process. And last month, Teva bought Taiyo Pharmaceutical Industry, Japan’s third-largest generics company, for $934 million.


August 24, 2011

Par Pharmaceutical Cos. will acquire Anchen Pharmaceuticals for $410 million, Par said Wednesday.

WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. will acquire Anchen Pharmaceuticals for $410 million, Par said Wednesday.

Based in Irvine, Calif., Anchen is a privately owned generic drug maker that expects to launch eight to 10 new generic drugs over the next two years. Par plans to finance the acquisition with a $350 million term loan and cash it already has.

August 19, 2011

While Indian generic drug maker Ranbaxy Labs is expected by many to launch a generic version of a cholesterol drug made by Pfizer later this year, it may have to sell its rights to it if it can't win Food and Drug Administration approval in time, according to published reports.

NEW YORK — While Indian generic drug maker Ranbaxy Labs is expected by many to launch a generic version of a cholesterol drug made by Pfizer later this year, it may have to sell its rights to it if it can't win Food and Drug Administration approval in time, according to published reports.

Citing Credit Suisse analysts, Bloomberg reported that the FDA may delay approval of Ranbaxy's version of Lipitor (atorvastatin), which would prevent it from marketing the drug starting Nov. 30, as it has planned to do.

August 10, 2011

Sunsweet Growers has acquired a maker of dietary supplement beverages.

YUBA CITY, Calif. — Sunsweet Growers has acquired a maker of dietary supplement beverages.

July 28, 2011

Pfizer has entered a definitive agreement to acquire a biopharmaceutical company that focuses on the development of pain treatments.

NEW YORK — Pfizer has entered a definitive agreement to acquire a biopharmaceutical company that focuses on the development of pain treatments.

Pfizer, which currently owns a near 11% stake in Icagen, will acquire the company's remaining 8.3 million shares. The aggregate transaction value, which includes the value of the shares currently owned by Pfizer, is about $56 million.

The two companies entered a discovery, development and commercialization collaboration in 2007, which sought to create potential treatments for pain and related disorders.

July 28, 2011

Revlon, which has been taking steps to improve its capital structure, posted a boost in second-quarter net sales, largely due to the inclusion of the recently acquired Sinful Colors brand and higher net sales of Revlon color cosmetics.

NEW YORK — Revlon, which has been taking steps to improve its capital structure, posted a boost in second-quarter net sales, largely due to the inclusion of the recently acquired Sinful Colors brand and higher net sales of Revlon color cosmetics.

"In the second quarter of 2011, consistent with our strategy of driving profitable growth, we delivered top line growth of 4%, while supporting our brands at appropriate levels and maintaining competitive operating margins," Revlon president and CEO Alan Ennis said.

July 27, 2011

Generic drug maker Perrigo has closed its purchase of Paddock Labs, the company said Tuesday.

ALLEGAN, Mich. — Generic drug maker Perrigo has closed its purchase of Paddock Labs, the company said Tuesday.

Perrigo acquired privately owned Paddock, a manufacturer of generic prescription and over-the-counter drugs based in Minneapolis, for $540 million.

“We are very pleased to welcome the Paddock team to the Perrigo family,” Perrigo chairman and CEO Joseph Papa said. “This acquisition is another important step forward in executing Perrigo’s strategy to expand our specialty portfolio of generic Rx products.”

July 25, 2011


One thing that was pretty clear in the research we conducted for the 2011 Retail Clinician Reader Survey is that an increasing number of retail-based health practitioners want the clinics they work for to expand the scope of services beyond acute care.


One thing that was pretty clear in the research we conducted for the 2011 Retail Clinician Reader Survey is that an increasing number of retail-based health practitioners want the clinics they work for to expand the scope of services beyond acute care. Many readers said the one thing that would make them even more satisfied about the work they do is “moving beyond sick care,” as one reader noted, to more preventive/wellness-oriented services, including chronic disease management programs for diabetes, hypertension and more.

July 25, 2011


When Rite Aid chairman Mary Sammons accepted the Sheldon W. Fantle Lifetime Achievement Award at the National Association of Chain Drug Stores’ Annual Meeting in Scottsdale, Ariz., in May, it was the culmination of a career that had seen Rite Aid emerge from a period of darkness that had lasted more than a decade.



When Rite Aid chairman Mary Sammons accepted the Sheldon W. Fantle Lifetime Achievement Award at the National Association of Chain Drug Stores’ Annual Meeting in Scottsdale, Ariz., in May, it was the culmination of a career that had seen Rite Aid emerge from a period of darkness that had lasted more than a decade.


Sammons plans to stay on as chairman of Camp Hill, Pa.-based Rite Aid until the company’s annual meeting in June 2012. But when she does hang up the gloves, she will have a lot to look back on.


July 22, 2011

Bristol-Myers Squibb will acquire San Diego-based Amira Pharmaceuticals for $325 million, the two companies said Friday.

NEW YORK — Bristol-Myers Squibb will acquire San Diego-based Amira Pharmaceuticals for $325 million, the two companies said Friday.

Amira develops pharmaceutical drugs for treating inflammatory and fibrotic diseases, and the deal includes milestone payments of up to $150 million on top of the upfront purchase price. Amira’s drugs include AM152, an investigational treatment for idiopathic pulmonary fibrosis, currently in early-stage clinical trials and set to enter mid-stage trials.

July 21, 2011

The merger agreement between Medco Health Solutions and Express Scripts announced Thursday has drawn objections from retail pharmacy trade groups.

ALEXANDRIA, Va. — The merger agreement between Medco Health Solutions and Express Scripts announced Thursday has drawn objections from retail pharmacy trade groups.

In a joint statement on Thursday, National Community Pharmacists Association EVP and CEO Douglas Hoey and National Association of Chain Drug Stores president and CEO Steve Anderson said Express Scripts’ $29.1 billion acquisition of Medco would “exacerbate [pharmacy benefit managers’] detrimental effect on pharmacy patient care.”

July 15, 2011

Valeant Pharmaceuticals has purchased a dermatology subsidiary from Johnson & Johnson, the Canadian drug maker said Friday.

MISSISSAUGA, Ontario — Valeant Pharmaceuticals has purchased a dermatology subsidiary from Johnson & Johnson, the Canadian drug maker said Friday.

The $345 million acquisition of the Ortho Dermatologics division of J&J subsidiary Janssen Pharmaceuticals follows Valeant’s $425 million purchase of Dermik, the skin care business of French drug maker Sanofi. Ortho Dermatologics’ portfolio includes the drugs Retin-A Micro, Ertaczo and Renova, which collectively had sales of about $150 million in 2010.